No abstract

The dramatic increase in genetic testing for adult‐onset diseases has created a debate regarding whether or not insurance companies should be able to use genetic test results in underwriting. We use data from women who have been tested for the BRCA1 gene mutation along with data from otherwise comparable untested women to assess the potential for adverse selection in the life insurance market when tested individuals know their genetic test results but insurers do not. Our analyses show that women who test positive for the BRCA1 gene mutation do not capitalize on their informational advantage by purchasing more life insurance than those women who have not undergone genetic testing. Am. J. Med. Genet. 93:29–39, 2000. © 2000 Wiley‐Liss, Inc.

Characteristics of included studies [ordered by study ID] Methods Concealment of allocation: No-quasi-randomised by date of birth (even dates=room air, odd dates=100% oxygen) Blinding of intervention: No Completeness of followup: Yes for short-term outcomes-100% followup for in-hospital outcomes but No for outcomes at 28 days (86%) Blinding of outcome measurement: No Participants Single centre study. 84 neonates with apnoea and/or heart rate < 80 bpm and a birth weight > 999 g. Interventions Room air (n=42) or 100% oxygen (n=42) via intermittent positive pressure ventilation (IPPV) with ambu bag and mask at 60 bpm. Backup use of 100% O2 allowed for room air group, if baby remained cyanotic or bradycardic at 90 sec (all infants analysed on an intention to treat basis). Outcomes Death. Arterial blood gas status at 10 and 30 minutes of life. Neurological examination at 0-3, 4-7 and 28 days of life. Notes This study was designed in Oslo, Norway and performed in New Delhi, India. It served as a pilot study for a bigger study (Saugstad 1998). Risk of bias Bias Authors' judgement Support for judgement Allocation concealment? High risk C-Inadequate Ramji 1993 Methods Concealment of allocation: No-quasi-randomised by date of birth (even dates=room air, odd dates=100% oxygen) Blinding of intervention: No Completeness of followup: Yes. Blinding of outcome measurement: No Participants Multicentred (4 Indian units) study. 431* neonates weighing more than 1000g having a heart rate <100/ minute and/or apneic and unresponsive to stimulation. Excluded lethal anomalies, hydrops fetalis, congenital pulmonary or cardiac defects. Interventions Room air (n=210) or 100% oxygen (n=221) via intermittent positive pressure ventilation (IPPV) with infant resuscitation bag and mask at 60 bpm. Backup use of 100% O2 allowed for room air group, if baby remained cyanotic or bradycardic at 90 sec (all infants analysed on an intention to treat basis).

No abstract

No abstract